Absci reported positive interim Phase 1 data for ABS-201, a novel anti-PRLR antibody for androgenetic alopecia, showing favorable safety, long half-life, and advancement into multiple-dose testing.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
Absci has reported positive interim Phase 1 results for ABS-201, an investigational anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia (AGA), the most common form of hair loss. Early data from the ongoing first-in-human HEADLINE trial showed favorable safety, tolerability, pharmacokinetic, and immunogenicity findings, supporting advancement into the multiple ascending dose (MAD) portion of the study.
The Phase 1/2a HEADLINE trial (NCT07317544) is evaluating ABS-201 in healthy adults with and without AGA. Interim findings include data from 32 participants enrolled across four single ascending dose (SAD) cohorts receiving intravenous doses of 150 mg, 450 mg, 900 mg, or 1800 mg. Participants were randomized in a 3:1 ratio to receive ABS-201 or placebo.
Novel Approach Targets Prolactin Receptor Signaling
ABS-201 is a monoclonal antibody that blocks prolactin receptor signaling, a pathway implicated in hair follicle regulation. The therapy aims to stimulate hair follicle regeneration and promote durable hair regrowth through a mechanism distinct from currently available treatments.
Androgenetic alopecia affects an estimated 80 million people in the United States. Existing FDA-approved therapies, including minoxidil and finasteride, provide modest benefits for many patients and can be associated with tolerability concerns, creating a need for alternative treatment options.
Interim Data Show Favorable Safety Profile
As of the June 8, 2026 data cutoff, ABS-201 appeared well tolerated across all blinded SAD cohorts. No treatment-emergent serious adverse events were reported.
Most adverse events were mild in severity. Investigators reported only one moderate treatment-emergent adverse event, a headache in the 900 mg cohort, which was considered unlikely to be related to study treatment. Treatment-related adverse events occurred in five participants and were all mild. Headache was the most commonly reported adverse event, occurring in four participants.
The safety review committee assessed the blinded safety and pharmacokinetic data and approved progression into the MAD phase of the trial.
Long Half-Life Supports Infrequent Dosing
Interim pharmacokinetic analyses showed an estimated ABS-201 half-life of at least 65 days across the SAD cohorts. If confirmed during continued follow-up, the extended half-life could support a dosing schedule of only two or three injections over a six-month treatment period.
The company also reported no apparent impact of anti-drug antibodies on pharmacokinetics, an encouraging early immunogenicity finding.
These characteristics may offer a potential advantage over existing hair-loss therapies that often require daily administration and long-term adherence.
Multiple-Dose Study Underway
The MAD portion of the HEADLINE trial has now begun in participants with androgenetic alopecia. This stage is evaluating subcutaneous doses of 300 mg, 600 mg, and 1200 mg or matching placebo.
Beyond safety and tolerability, investigators will assess pharmacokinetics, pharmacodynamics, target area hair count, hair width, pigmentation changes, and patient- and investigator-reported outcomes.
Chief Medical Officer Dr. Ransi Somaratne said the emerging safety, pharmacokinetic, and immunogenicity profile supports continued development of ABS-201 and progression into later-stage evaluation. The company also plans to initiate a Phase 2 study in endometriosis later this year.
Absci expects to report interim proof-of-concept data from the ongoing HEADLINE study during the second half of 2026, followed by full proof-of-concept results in early 2027.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.